New Delhi: MedGenome, a leading global genomics-driven diagnostics and research services company, marks a decade of transformative contributions to healthcare. Founded in 2013, the company has been at the forefront of integrating genomics into clinical practice.
To commemorate its tenth anniversary, MedGenome has launched its corporate video [10 Years of Pioneering Genomics], showcasing the company’s decade-long journey in the field of genomics. This film pays tribute to the company’s dedicated partners—investors, clinicians, scientists, bioinformaticians, lab technicians, and more than 1100 employees who have tirelessly worked to advance science and technology in addressing complex diseases and providing reliable, innovative diagnostic solutions in India.
With the hashtag #10yearsofpioneeringgenomics, MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all sections of society. MedGenome will continue to be guided by its vision to enhance healthcare affordability and accessibility and focus on its mission to leverage genomics to address the huge unmet need across emerging markets.
Some of MedGenome’s key achievements include:
-
First in India to introduce tests like validated Non-invasive prenatal testing (NIPT) for identifying chromosomal abnormalities in the fetus, liquid biopsy (OncoTrack) – a non-invasive alternative to tissue biopsy, SPIT Seq that identifies MDR TB through culture free whole genome sequencing; and whole exome sequencing to identify mutations of rare diseases.
-
Founding member of GenomeAsia 100K, an initiative to sequence 100,000 South Asian genomes. This data is now instrumental in global research efforts and advancements in precision medicine.
-
Sequenced over 350,000 exomes and genomes, contributing to a deeper understanding of genetic disorders.
-
Partnered with more than 5,500 hospitals and engaged more than 15,000 clinicians across India, making genetic testing more accessible.
-
Collaborated with renowned institutions such as Stanford University, Harvard Medical School, and the National Institutes of Health, resulting in several significant discoveries. For example, MedGenome’s research has identified rare genetic variants associated with complex diseases like cardiovascular disorders and neurological conditions, providing valuable insights for personalized treatment approaches.
-
Partnered with Twist Bioscience, to establish the HOPE for Rare Diseases Program in India. Within the program, discounted whole exome sequencing is provided to the patients from economically disadvantaged families.
-
The company employs state-of-the-art next-generation sequencing platforms and proprietary AI-driven analytics to decipher complex genomic information. Through its machine learning algorithms, MedGenome has developed predictive models that aid in identifying disease risk factors, optimizing drug responses, and guiding targeted therapies.